Table 2.
Screening for abscopal effects after radioembolization
| Comparison of untreated metastases in MRI 1 (baseline) and MRI 2 (follow-up after first RE) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| RECIST 1.0 (96 patients) | Response of lesions (765 checked for AE) | ||||||||||
| Complete response (CR) | 0 | Complete response—0 metastases | |||||||||
| Partial response (PR) | 2 | Shrinkage > 30%—6 metastases (2 patients) | |||||||||
| Stable disease (SD) | 35 | Shrinkage < 30%—2 metastases (2 patients) | |||||||||
| Progressive disease (PD) | 61 | No shrinkage or progression – 757 metastases | |||||||||
| Patients with PR | |||||||||||
| Patient A (compare Fig. 2) (female, age 43, BCA) |
04/2010—initial diagnosis of bilateral breast cancer 12/2013—first detection of liver metastases (ER +, PR +, Her2neu-) Endocrine therapy with Tamoxifen und GnRH analogues Decision for radioembolization due to progressive hepatic disease 10/2015 radioembolization of the right liver lobe + S4b (1270 MBq) Abscopal effect registered (acquisition of MRI2 42 days after MRI1 and 43 days after first RE) 11/2015 radioembolization of the left liver lobe (640 MBq) 5/16 stable disease Lost in further follow-up |
||||||||||
| Shrinkage of metatsases (mm) | MRI1 | MRI2 | |||||||||
| 18 | 19 | 31 | 14 | 14 | 19 | ||||||
| Patient B (compare Fig. 3) (male, age 65, Prostate CA) |
03/1995—initial diagnosis of prostate cancer 01/2002—first detection of liver metastases chemotherapy cycles with: estramustine, docetaxel, capecitabine, imatinib – until 04/2005 06/2005—11/2006 multiple local ablations (interstitial brachytherapy) of liver metastases 11/2007 radioembolization of the right liver lobe (850 MBq) Questionable Abscopal effect registered (acquisition of MRI2 42 days after MRI1 and 43 days after first RE) 01/2008 radioembolization of the left liver lobe (400 MBq) 09/2008 deceased |
||||||||||
| Shrinkage of metatsases (mm) | MRI1 | MRI2 | |||||||||
| 10 | 20 | 24 | 28 | 34 | 10 | 14 | 24 | 21 | 27 | ||